0.15
-0.003(-2.01%)
Currency In HKD
Address
No. 20 Science Park East Avenue
Sha Tin,
Hong Kong
Phone
852 3102 3232
Sector
Healthcare
Industry
Biotechnology
Employees
487
First IPO Date
November 12, 2001
| Name | Title | Pay | Year Born |
| Mr. Zhi Gang Zhao CPA, MSc | Chief Executive Officer & Executive Director | 1.17M | 1965 |
| Mr. Dawei Chen EMBA | Executive Vice Chairman of the Board | 378,000 | 1970 |
| Dr. Ya Lei Wen | Chief Operating Officer & Executive Director | 1.15M | 1961 |
| Mr. Kingsley Leung AHKIoD, CFA, MSc | Executive Chairman of the Board | 2.11M | 1987 |
| Ms. Jing Li | Head of R&D Department | 0 | 1980 |
| Mr. Wenming Chen | Head of the Medical & Registration Department | 0 | 1987 |
| Ms. Wing Yan Ho A.C.I.S., A.C.S., ACS (PE), ACS(PE), P.E. | Company Secretary | 0 | 1981 |
| Mr. Kai Du | Financial Controller | 0 | 1981 |
| Ms. Wei Tian | Head of HR & Administration Department | 0 | 1984 |
| Mr. Wen Du An | Head of Marketing & Sales | 0 | 1983 |
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF eye drop for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. It is also developing prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; and rhPTH 1-34 (Uni-PTH) for the treatment of osteoporosis in postmenopausal women, as well as Uni-GLP, a GLP-1 agonist, a non-insulin treatment candidate for the treatment of Type 2 diabetes. The company was founded in 2001 and is headquartered in Sha Tin, Hong Kong.